Related references
Note: Only part of the references are listed.Observation of hepatotoxicity during long-term gefitinib administration in patients with non-small-cell lung cancer
Jingjing Wang et al.
ANTI-CANCER DRUGS (2016)
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial
Keunchil Park et al.
LANCET ONCOLOGY (2016)
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6
James C-H Yang et al.
LANCET ONCOLOGY (2015)
Impact of single nucleotide polymorphisms on severe hepatotoxicity induced by EGFR tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring EGFR mutations
Eri Sugiyama et al.
LUNG CANCER (2015)
Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer
Masayuki Takeda et al.
LUNG CANCER (2015)
Rociletinib in EGFR-Mutated Non-Small-Cell Lung Cancer
L. V. Sequist et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
AZD9291 in EGFR Inhibitor-Resistant Non-Small-Cell Lung Cancer
Pasi A. Jaenne et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Gefitinib and Erlotinib in Metastatic Non-Small Cell Lung Cancer: A Meta-Analysis of Toxicity and Efficacy of Randomized Clinical Trials
Mauricio Burotto et al.
ONCOLOGIST (2015)
Class act: safety comparison of approved tyrosine kinase inhibitors for non-small-cell lung carcinoma
Mauricio Burotto et al.
EXPERT OPINION ON DRUG SAFETY (2015)
First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study
J-Y Douillard et al.
BRITISH JOURNAL OF CANCER (2014)
Use of Statins and the Risk of Death in Patients With Prostate Cancer
Oriana Yu et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER)
Yuankai Shi et al.
JOURNAL OF THORACIC ONCOLOGY (2014)
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
Yi-Long Wu et al.
LANCET ONCOLOGY (2014)
Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naive non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002)
A. Inoue et al.
ANNALS OF ONCOLOGY (2013)
Gefitinib-Related Interstitial Lung Disease in Taiwanese Patients With Non-Small-Cell Lung Cancer
Shih-Chieh Chang et al.
CLINICAL LUNG CANCER (2013)
Polymorphisms of CYP2D6 Gene and Gefitinib-Induced Hepatotoxicity
Takayuki Takimoto et al.
CLINICAL LUNG CANCER (2013)
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
Lecia V. Sequist et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: Post hoc analyses from the IPASS study
Yi-Long Wu et al.
LUNG CANCER (2013)
First-SIGNAL: First-Line Single-Agent Iressa Versus Gemcitabine and Cisplatin Trial in Never-Smokers With Adenocarcinoma of the Lung
Ji-Youn Han et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
Rafael Rosell et al.
LANCET ONCOLOGY (2012)
Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy
Seung Tae Kim et al.
LUNG CANCER (2012)
Target Binding Properties and Cellular Activity of Afatinib (BIBW 2992), an Irreversible ErbB Family Blocker
Flavio Solca et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2012)
Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors Focus on 4-Anilinoquinazolines
Matthias Scheffler et al.
CLINICAL PHARMACOKINETICS (2011)
Safe and Successful Treatment With Erlotinib After Gefitinib-Induced Hepatotoxicity: Difference in Metabolism As a Possible Mechanism
Takashi Kijima et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non-Small-Cell Lung Cancer in Asia (IPASS)
Masahiro Fukuoka et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
Caicun Zhou et al.
LANCET ONCOLOGY (2011)
Comparison of gefitinib and erlotinib in advanced NSCLC and the effect of EGFR mutations
Jenn-Yu Wu et al.
LUNG CANCER (2011)
Differences in adverse events between 250 mg daily gefitinib and 150 mg daily erlotinib in Japanese patients with non-small cell lung cancer
Yosuke Togashi et al.
LUNG CANCER (2011)
Randomized Phase III Trial of Gefitinib versus Docetaxel in Non-Small Cell Lung Cancer Patients Who Have Previously Received Platinum-Based Chemotherapy
Dae Ho Lee et al.
CLINICAL CANCER RESEARCH (2010)
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
Tetsuya Mitsudomi et al.
LANCET ONCOLOGY (2010)
Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer with Mutated EGFR.
Makoto Maemondo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Randomized Phase II Study of Gefitinib Compared With Placebo in Chemotherapy-Naive Patients With Advanced Non-Small-Cell Lung Cancer and Poor Performance Status
Glenwood Goss et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
First-Line Gefitinib for Patients With Advanced Non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations Without Indication for Chemotherapy
Akira Inoue et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer.
Rafael Rosell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma.
Tony S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Interstitial lung disease in Japanese patients with lung cancer - A cohort and nested case-control study
Shoji Kudoh et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2008)
EGFR Mutations Predict Survival Benefit From Gefitinib in Patients With Advanced Lung Adenocarcinoma: A Historical Comparison of Patients Treated Before and After Gefitinib Approval in Japan
Toshimi Takano et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE):: A randomized, phase II study
Lucio Crino et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer
Riichiroh Maruyama et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy
Chih-Hsin Yang et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial
Edward S. Kim et al.
LANCET (2008)
Drug insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy
Yohann Loriot et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2008)
Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer
Fred R. Hirsch et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Mechanisms of cutaneous toxicities to EGFR inhibitors
Mario E. Lacouture
NATURE REVIEWS CANCER (2006)
Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: Subset analysis from the ISEL study
Alex Chang et al.
JOURNAL OF THORACIC ONCOLOGY (2006)
Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib
M Ando et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer
Tania Cufer et al.
ANTI-CANCER DRUGS (2006)
Exploring the relationship between expression of cytochrome P450 enzymes and gefitinib pharmacokinetics
Helen C. Swaisland et al.
CLINICAL PHARMACOKINETICS (2006)
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
N Thatcher et al.
LANCET (2005)
ERBB receptors and cancer: The complexity of targeted inhibitors
NE Hynes et al.
NATURE REVIEWS CANCER (2005)
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers
H Shigematsu et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
EGFR mutations in non-small-cell lung cancer:: Analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment
A Marchetti et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Follicular drug eruption induced by gefitinib (ZD 1839, Iressa): Clinical picture correlates with in vitro data of focal epidermal necrosis after epidermal growth factor inhibition in skin cultures
R Treudler et al.
DERMATOLOGY (2005)
United States Food and Drug Administration drug approval summary: Gefitinib (ZD1839; Iressa) tablets
MH Cohen et al.
CLINICAL CANCER RESEARCH (2004)
Complications of therapy in cancer patients - Case 1. Paronychia and skin hyperpigmentation induced by gefitinib in advanced non-small-cell lung cancer
GC Chang et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
EGFR mutations in lung cancer:: Correlation with clinical response to gefitinib therapy
JG Paez et al.
SCIENCE (2004)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
TJ Lynch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Gefitinib in elderly and unfit patients affected by advanced non-small-cell lung cancer
C Gridelli et al.
BRITISH JOURNAL OF CANCER (2003)
Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer - A randomized trial
MG Kris et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2003)
Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer
M Fukuoka et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors
K Nakagawa et al.
ANNALS OF ONCOLOGY (2003)
Paronychia induced by Gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor
J Nakano et al.
JOURNAL OF DERMATOLOGY (2003)
Severe acute interstitial pneumonia and gefitinib
A Inoue et al.
LANCET (2003)
Lessons from the 'Iressa' Expanded Access Programme: gefitinib in special non-small-cell lung cancer patient populations
R Stahel et al.
BRITISH JOURNAL OF CANCER (2003)
Development of multiple paronychia and periungual granulation in patients treated with gefitinib, an inhibitor of epidermal growth factor receptor
T Dainichi et al.
DERMATOLOGY (2003)
Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types
J Baselga et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: Results of a phase I trial
RS Herbst et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: Results of a phase I trial
M Ronson et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Pharmacokinetics and tolerability of the orally active selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in healthy volunteers
H Swaisland et al.
CLINICAL PHARMACOKINETICS (2001)
Share Paper
